SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression

Qing Nian; Jingwei Li; ZhongYu Han; Qi Liang; Maoyu Liu; Chan Yang; Fernando Rodrigues-Lima; Tao Jiang; Liyun Zhao; Jinhao Zeng; Chi Liu; Jianyou Shi

doi:10.1016/j.biopha.2022.113519

SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression

Biomed Pharmacother. 2022 Sep:153:113519. doi: 10.1016/j.biopha.2022.113519. Epub 2022 Aug 16.

Authors

Qing Nian¹, Jingwei Li¹, ZhongYu Han², Qi Liang³, Maoyu Liu⁴, Chan Yang⁵, Fernando Rodrigues-Lima⁶, Tao Jiang⁷, Liyun Zhao⁴, Jinhao Zeng⁸, Chi Liu⁹, Jianyou Shi¹⁰

Affiliations

¹ Transfusion Department, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.
² School of Medical and Life Sciences, Reproductive and Women-Children Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
³ College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan 611756, China.
⁴ Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
⁵ Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, Sichuan, China.
⁶ Unité de Biologie Fonctionnelle et Adaptative, Université de Paris, Paris 75013, France.
⁷ Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.
⁸ Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address: zengjinhao@cdutcm.edu.cn.
⁹ Renal Department and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu 610072, China. Electronic address: liuchi_1230@163.com.
¹⁰ Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China. Electronic address: shijianyoude@126.com.

PMID: 36076604
DOI: 10.1016/j.biopha.2022.113519

Abstract

Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40, is a matricellular protein involved in several biological processes including cell adhesion, growth factor availability, extracellular matrix remodeling and immune-regulation. SPARC has also been associated with a variety of diseases including diabetes, colon cancer, and leukemia. The expression of SPARC in different diseases exhibits some degree of ambiguity, especially in hemopathies. Herein, we review the current expression and effects of SPARC in various hematologic disorders with respect to nanoparticle albumin bound innovative therapies and related diagnostic research, providing a clinical perspective on the use of NAB technology in the frontier treatment of hematologic diseases.

Keywords: Hematologic malignancies; NAB; SPARC; Targeted therapy.

Publication types

Review

MeSH terms

Albumins
Cell Adhesion
Extracellular Matrix / metabolism
Hematologic Diseases / genetics
Hematologic Diseases / metabolism
Hematologic Neoplasms* / genetics
Hematologic Neoplasms* / metabolism
Humans
Osteonectin* / genetics
Osteonectin* / metabolism

Substances

Albumins
Osteonectin
SPARC protein, human